OmniAb Inc. $(OABI)$ has reported its financial results for the second quarter and the first half of 2025. The company experienced a net loss of $15.9 million in the second quarter, compared to a net loss of $13.6 million in the same period of 2024. For the first half of 2025, the net loss was $34.1 million, slightly higher than the $32.6 million loss recorded in the first half of 2024. Revenue for the first half of 2025 was $8.1 million, a decrease from $11.4 million in the same period of the previous year. This decline was attributed primarily to a reduction in milestone revenue by $0.8 million, although there was an increase in license revenue by $0.2 million. Service revenue fell due to the discontinuation of a small-molecule ion channel program. However, these decreases were partially offset by $0.7 million gained from xPloration revenue through the sale of an instrument and related consumables. As of June 30, 2025, OmniAb had $41.6 million in cash, cash equivalents, and short-term investments. The company's financial guidance for 2025 projects revenue to be between $20 million to $25 million, with costs and operating expenses expected to range from $85 million to $90 million. OmniAb anticipates a reduction in cash use for 2025 compared to the $38.9 million used in 2024, excluding ATM issuance. The effective tax rate for the full year 2025 is projected to be approximately 0%. The company highlighted its achievements in expanding partnerships, reaching 100 active partners in the second quarter, and launching the xPloration® Partner Access Program to enhance revenue streams. Chief Executive Officer Matt Foehr emphasized the strength of OmniAb's technology platform and operational streamlining efforts to boost scalability and long-term value.